Latest Catheter ablation Stories
Study shows noninvasive, fast way to map heart's electrical activity in one heartbeat.
Results presented today from the Atrial Fibrillation Ablation Pilot Study show that almost 40% of patients undergoing a catheter ablation for atrial fibrillation have no underlying disease associated with the arrhythmia, and precipitating factors are rare.
MARLBOROUGH, Mass., June 29, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight(TM) Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announced today that its technology was featured in a live case and scientific abstract presented at the European Heart Rhythm Association (EHRA) EUROPACE 2011 congress on June 28 in Madrid, Spain.
Doctors at Washington University School of Medicine in St. Louis are performing a new procedure to treat atrial fibrillation, a common irregular heartbeat.
MARLBOROUGH, Mass., June 22, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight(TM) Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announced today that its technology will be the subject of several scientific sessions at the upcoming European Heart Rhythm Association (EHRA) EUROPACE 2011 congress, June 26-29 in Madrid, Spain.
ST. LOUIS, June 1, 2011 /PRNewswire/ -- Missouri Baptist Medical Center today opened a new Arrhythmia Center, within its regionally acclaimed Heart Center, to meet the needs of an increasing population of patients suffering from abnormal heart rhythms.
The electrophysiology team at the Montreal Heart Institute (MHI) used cryoablation (ablation using cold) to treat a patient suffering from atrial fibrillation, the most common form of cardiac arrhythmia, and one associated with significant morbidity.
MARLBOROUGH, Mass., May 9, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the transcatheter treatment of Atrial Fibrillation (AF), announced its technology enables a Pulmonary Vein (PV) acute isolation rate of nearly 99%, with approximately 86% of PVs remaining persistently isolated after three months.
ST. LOUIS, May 4, 2011 /PRNewswire/ -- Stereotaxis' (Nasdaq: STXS) continued leadership in the remote treatment of a broad spectrum of complex arrhythmias will again be prominently detailed in the scientific program of the 32nd Annual Heart Rhythm Scientific Sessions in San Francisco, California.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).